One day late, but wanted to summarize #PancreaticCancer #PancSM talks from yesterday’s #ASTRO20 session on hypofractionation in GI Cancers before spill the beans on my study... 1/9
@MikeChoungMD gave a great talk on the @UMiami experience with #MRLinac for #PancreaticCancer #PancSM. This is a great technology that allows #RadOnc to replan the treatment each day based on the anatomy of the nearby bowel. #ASTRO20 2/9
In this study on #MRLinac, they showed that they can safely deliver ablative doses (about 50Gy/5 fractions) with less than 2% acute and late GI tox. #ASTRO20 3/9
For the aficionados, they used a duodenal constraint of V35<0.5cc and a point max dose of 40Gy. The constraints from our trial using #SBRT and #GC4419 for #PancreaticCancer #PancSM were actually a bit more generous at V35<1cc and V40<0.5cc. #ASTRO20 4/9
Next, Michelle Barrord from University of Cincinnati about the dose and volume of RT affected surgical outcomes in borederline resectable #PancreaticCancer #PancSM #ASTRO20 5/9
TL;DR If you covered the tumor and the locogregional nodes to a modest 31.3Gy (EQD2) to the you had better outcomes. #ASTRO20 6/9
Of note, 5Gyx5 has an EQD2=31.25Gy and was note tied to better outcomes. Important, because although 6.6 Gy x5 is considered standard, 5Gyx5 is given in some institutions. #ASTRO20 7/9
On that note,@TedHong9 from @MGHCancerCenter showed the results of their trial using and autophagy inhibitor with preoperative proton therapy for borderline resectable #PancreaticCancer #PancSM. #ASTRO20 8/9
TL;DR: The addition of hydroxychloroquine didn’t change outcomes significantly, but there is still some signal that it might affect PFS in BR #PancreaticCancer #PancSM. #ASTRO20 9/9
• • •
Missing some Tweet in this thread? You can try to
force a refresh
